These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 31047340)

  • 1. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
    Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
    Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
    Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
    Kamei M; Terasaki H; Yoshimura N; Shiraga F; Ogura Y; Grotzfeld AS; Pilz S; Ishibashi T
    Acta Ophthalmol; 2017 Feb; 95(1):e29-e35. PubMed ID: 27654837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study.
    Glacet-Bernard A; Girmens JF; Kodjikian L; Delcourt C; Fajnkuchen F; Creuzot-Garcher C; San Nicolas N; Massin P
    Ophthalmic Res; 2023; 66(1):824-834. PubMed ID: 36972579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
    Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
    Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion: A Randomized Clinical Trial.
    McAllister IL; Smithies LA; Chen FK; Mackey DA; Sanfilippo PG
    JAMA Ophthalmol; 2018 Dec; 136(12):1391-1397. PubMed ID: 30347030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
    Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
    Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
    Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
    Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
    Hattenbach LO; Feltgen N; Bertelmann T; Schmitz-Valckenberg S; Berk H; Eter N; Lang GE; Rehak M; Taylor SR; Wolf A; Weiss C; Paulus EM; Pielen A; Hoerauf H;
    Acta Ophthalmol; 2018 Feb; 96(1):e10-e18. PubMed ID: 28251811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
    Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
    Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.